Live Breaking News & Updates on நோவர்த்திச் பார்மா தகவல்தொடர்புகள்

Stay updated with breaking news from நோவர்த்திச் பார்மா தகவல்தொடர்புகள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis presents positive Phase III results from JUNIPERA study supporting Cosentyx® as a potential treatment in a JIA population at EULAR 2021

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis presents positive Phase III results from JUNIPERA study supporting Cosentyx® as a potential treatment in a JIA population at EULAR 2021 ....

United States , Isabella Zinck , Michael Meo , Thomas Hungerbuehler , Dermatol Venereol , Louise Clark , Samir Shah , Julie Masow , Sloan Simpson , Rheumatology Research Alliance Registry , Novartis Us External Communications , Exchange Commission , International League , Novartis Europharm , Novartis Pharma Communications , Novartis Pharmaceuticals Corp , Novartis Global External Communications , Juvenile Idiopathic , Enthesitis Related Arthritis , Juvenile Psoriatic Arthritis , Primary Results , Treatment Withdrawal , Rheumatol Online , Childhood Arthritis , Rheumatology Research Alliance , Provides Sustained Improvements ,

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis

NOVARTIS AG CHF0.50(REGD)
Novartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis
Novartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis
Approval for moderate to severe pediatric patients six years and older is based on pivotal trial data showing
Cosentyx demonstrated superior improvements of skin symptoms compared to placebo
1
The safety profile of Cosentyx in pediatric patients with plaque psoriasis was demonstrated in two Phase III trials and is consistent with the established adult psoriasis indication
1
Plaque psoriasis is a chronic, inflammatory disease that may impact up to 350,000 children worldwide, with onset most common during adolescence ....

University Of Texas , United States , San Antonio , John Browning , Novartis Cosentyx , Isabella Zinck , Michael Meo , Thomas Hungerbuehler , Louise Clark , Samir Shah , Julie Masow , Dermatol Venerol , Sloan Simpson , University Of Texas Health , Drug Administration , Novartis Us External Communications , Exchange Commission , Novartis Europharm , Novartis Pharma Communications , American Academy Of Dermatology , National Psoriasis Foundation , Novartis Global Head Development Unit Immunology , Novartis Pharmaceuticals Corp , Novartis Global External Communications , Adjunct Associate Professor , Texas Health ,

Novartis Pharma AG: Novartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis

Novartis Pharma AG: Novartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis
Cosentyx demonstrated superior improvements of skin symptoms compared to placebo
1
The safety profile of Cosentyx in pediatric patients with plaque psoriasis was demonstrated in two Phase III trials and is consistent with the established adult psoriasis indication
1
Plaque psoriasis is a chronic, inflammatory disease that may impact up to 350,000 children worldwide, with onset most common during adolescence
2,3
Basel, June 1, 2021 - Novartis, a leader in immuno-dermatology and rheumatology, today announced the U.S. Food and Drug Administration (FDA) has approved Cosentyx ....

University Of Texas , United States , San Antonio , John Browning , Isabella Zinck , Michael Meo , Thomas Hungerbuehler , Louise Clark , Samir Shah , Julie Masow , Dermatol Venerol , Sloan Simpson , University Of Texas Health , Drug Administration , Novartis Us External Communications , Exchange Commission , Novartis Europharm , Novartis Pharma Communications , American Academy Of Dermatology , National Psoriasis Foundation , Novartis Global Head Development Unit Immunology , Novartis Pharmaceuticals Corp , Novartis Global External Communications , Adjunct Associate Professor , Texas Health , Angelika Jahreis ,